Targeted treatment with drugs that ameliorate mitochondrial function by inhibiting the expression of Drp1 and restoring the expression of Mfn2 have been reported to ameliorate AKI (Ishimoto and Inagi 2016). Here, DNM1L is linked to acute kidney injury.